[Federal Register Volume 66, Number 62 (Friday, March 30, 2001)]
[Notices]
[Page 17431]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-7877]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration


Joint Meeting of the Nonprescription Drugs Advisory Committee and 
the Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). The meeting will 
be open to the public.
    Name of Committees: Nonprescription Drugs Advisory Committee and 
the Pulmonary-Allergy Drugs Advisory Committee.
    General Function of the Committees: To provide advice and 
recommendations to the agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on May 11, 2001, 8 a.m. to 
5 p.m.
    Location: Holiday Inn, Two Montgomery Village Ave., Gaithersburg, 
MD.
    Contact: Sandra L. Titus or Kimberly L. Topper, Center for Drug 
Evaluation and Research (HFD-21), Food and Drug Administration, 5600 
Fishers Lane, (for express delivery, 5630 Fishers Lane, rm. 1093) 
Rockville, MD 20857, 301-827-7001, or e-mail: [email protected], or 
FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 
in the Washington, DC area), codes 12541 and 12545. Please call the 
Information Line for up-to-date information on this meeting.
    Agenda: The committees will consider citizen petition 98P-0610/CP1, 
submitted by Blue Cross of California, that requested the agency to 
convert fexofenadine hydrochloride, loratadine, and cetirizine 
hydrocholoride to over-the-counter (OTC) status.
    Background material, including the petition to switch the 
antihistamines to OTC status, is available at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm. Click on the year 2001 and go to the May 11th 
Nonprescription Drugs Advisory Committee file.
    Procedure: Interested persons may present data, information, or 
views, orally or in writing, on issues pending before the committee. 
Written submissions may be made to the contact person by May 2, 2001. 
Oral presentations from the public will be scheduled between 
approximately 9 a.m. and 9:30 a.m. and between approximately 1 p.m. and 
1:30 p.m. Time allotted for each presentation may be limited. Those 
desiring to make formal oral presentations should notify the contact 
person before May 2, 2001, and submit a brief statement of the general 
nature of the evidence or arguments they wish to present, the names and 
addresses of proposed participants, and an indication of the 
approximate time requested to make their presentation.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: March 22, 2001.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 01-7877 Filed 3-29-01; 8:45 am]
BILLING CODE 4160-01-S